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CLOSING THE GAP: PROTECTING PREDICTIVE
NEUROSCIENCE INFORMATION FROM HEALTH
INSURANCE DISCRIMINATION
ABSTRACT
Recent neuroscience advances have made it possible to predict illnesses,
such as Alzheimer’s disease, before the onset of any symptoms. This capability
is similar to the use of genetic information to predict illness, which began to
emerge roughly twenty-five years ago. While predictive information is
incredibly useful, the benefits come with a heavy cost. Predictive information
can easily be used as a basis for unfair discrimination by health insurance
companies, a problem exacerbated by the fact that predictive information is far
from perfect. Congress acknowledged and addressed this concern when it
preemptively passed the Genetic Information Nondiscrimination Act to
prohibit unfair health insurance discrimination on the basis of genetic
information. Congress further reinforced and expanded the protections
afforded to predictive genetic information with the passage of the Affordable
Care Act. However, no analogous protection has been afforded to predictive
neuroscience information, which can provide roughly the same information
that genetic information can.
This Comment argues that there is a gap in protection for predictive
neuroscience information in the large-group and self-insured health insurance
markets. This gap is significant because it allows health insurers to undercut
the protections afforded to predictive genetic information by the Genetic
Information Nondiscrimination Act and the Affordable Care Act. In order to
close the gap, this Comment proposes the addition of a health-status-related
factor in the Affordable Care Act for predictive neuroscience information. This
solution would bring the health insurance discrimination protections for
predictive neuroscience information in line with those that already exist for
predictive genetic information.
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INTRODUCTION
Technology in the health industry has grown by leaps and bounds, allowing
doctors to detect illnesses earlier and intervene in more effective ways. One of
the most amazing health-related advances in recent years has been the ability
to predict illnesses before any symptoms manifest.1 Genetic information first
opened the door to harnessing this predictive power, and the technology has
advanced rapidly, giving medical professionals insight they could only have
dreamed of just twenty-five years ago.2 But with this predictive power also
came the potential for abuse and unfair discrimination by health insurance
companies.3 Congress saw this negative potential and did something
unprecedented, preemptively shutting the door on unfair genetic discrimination
by passing the Genetic Information Nondiscrimination Act (GINA) in 2008.4
Just a few years later, another predictive modality has begun to emerge in
the form of predictive neuroscience. Neuroscience researchers have realized
how useful their findings could be for healthcare and medicine in adding to the
predictive power already being harnessed by genetic information.5 It has
become increasingly clear that, in many ways, genetic information and
neuroscience information are analogous and tend to reinforce one another,
thereby enhancing the strength of the predictive powers of each.6 However,
while GINA and parts of the Patient Protection and Affordable Care Act
(ACA) protect predictive genetic information from unfair health insurance

1

This idea will be discussed in detail in Part III of this Comment.
See U.S. Dep’t of Energy Human Genome Project, About the Human Genome Project, HUM. GENOME
PROJECT INFO. ARCHIVE 1990–2003, http://web.ornl.gov/sci/techresources/Human_Genome/project/
index.shtml (last modified Feb. 11, 2015) [hereinafter About the Human Genome Project] (describing the
achievements of the Human Genome Project).
3 This comment distinguishes between fair and unfair discrimination in the insurance context.
4 See Jessica L. Roberts, Preempting Discrimination: Lessons From the Genetic Information
Nondiscrimination Act, 63 VAND. L. REV. 439, 440–41 (2010) (discussing GINA’s unique preemptive nature).
5 See Steven K. Erickson, Blaming the Brain, 11 MINN. J.L. SCI. & TECH. 27 (2010) (discussing
advances in neuroscience relating to criminal culpability); Philip E. Tetlock, Gregory Mitchell & L. Jason
Anastasopoulos, Detecting and Punishing Unconscious Bias, 42 J. LEGAL STUD. 83 (2013) (discussing
neuroscience and bias detection).
6 For example, the apoE4 gene is a risk gene for developing Alzheimer’s disease, but researchers can
also predict Alzheimer’s disease through neuroimaging of amyloid plaques in the brain. See Press Release,
Am. Acad. of Neurology, Plaque Build-up in Your Brain May Be More Harmful Than Having Alzheimer’s
Gene (Oct. 15, 2012), available at http://www.sciencedaily.com/releases/2012/10/121015161912.htm; Press
Release, Perelman School of Med. at the Univ. of Pa., Path of Plaque Buildup in Brain Shows Promise as
Early Biomarker for Alzheimer’s Disease (July 15, 2013), available at http://www.sciencedaily.com/
releases/2013/07/130715105128.htm; What We Know Today About Alzheimer’s Disease, ALZHEIMER’S ASS’N,
http://www.alz.org/research/science/alzheimers_disease_causes.asp (last visited Apr. 27, 2015).
2
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discrimination,7 predictive neuroscience information has not been afforded
analogous protection. Given the strong connection between the predictive
information that can be gleaned from both genetic and neuroscience
information, it is apparent that one can be used to supplant the other, especially
when only predictive genetic information is protected.8
Health insurers make money based on their ability to underwrite risk and
identify who will be healthy and who will be sick, highly incentivizing them to
find any legal means of doing so.9 Because predictive neuroscience
information can give health insurers essentially the same knowledge as
predictive genetic information,10 predictive neuroscience information can be
used in place of predictive genetic information to get around the protections
that GINA and ACA afford to genetic information.
This Comment addresses the disparity in protections afforded to predictive
genetic information and predictive neuroscience information, arriving at the
conclusion that predictive neuroscience information should be protected from
health insurance discrimination in the same way that genetic information is
protected. Part I will begin by briefly introducing GINA and discussing why it
was enacted. It will present the backdrop against which GINA was proposed
and passed. Part I will also discuss the protections afforded by Title I of GINA
and why Title I was so important. It will conclude by exploring arguments
supporting and opposing GINA’s passage.
Part II will discuss additional existing health insurance discrimination
protections currently in place. The Health Insurance Portability and
Accountability Act’s (HIPAA) relevant protections and limitations will be
discussed first, followed by a brief overview of ACA’s protections. Part II will

7 See Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119 (2010) (codified in
scattered sections of Internal Revenue Code and Titles 29 and 42 of the United States Code); Genetic
Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, 122 Stat. 881 (2008) (codified as amended
in scattered sections of the Internal Revenue Code and Titles 29 and 42 of the United States Code).
8 See supra notes 5–6.
9 Health insurers are incentivized to utilize medical underwriting to offset the effects of adverse
selection in the health insurance market because they know that (1) “[p]eople are more likely to buy insurance
if they have reason to believe they will incur high costs in the near future” and (2) “[a] small proportion of the
insured population accounts for a very large share of total claims costs.” MARK MERLIS, NAT’L HEALTH
POLICY FORUM, FUNDAMENTALS OF UNDERWRITING IN THE NONGROUP HEALTH INSURANCE MARKET: ACCESS
TO COVERAGE AND OPTIONS FOR REFORM 5 (2005), http://www.nhpf.org/library/background-papers/
bp_underwriting_04-13-05.pdf.
10 See supra note 6.

SHIN GALLEYS PROOFS

2015]

4/29/2015 1:21 PM

CLOSING THE GAP

1437

conclude with a discussion about the trend toward greater health insurance
discrimination protections.
Part III will introduce the emergence of predictive neuroscience. It will
begin by discussing the increasing relevance of predictive neuroscience
information and then move on to give concrete examples of how this
information can be used to predict illnesses today, with the aim of
demonstrating that this is an increasingly relevant problem and that use of this
information for discriminatory purposes is entirely feasible given the current
state of the technology.
Part IV will argue that predictive neuroscience information should be
protected in the same way that predictive genetic information is protected from
health insurance discrimination under GINA and ACA. Part IV will
demonstrate that while predictive genetic information is fully protected from
health insurance discrimination, there is a gap in the existing protections that
allows health insurers in the large-group and self-insured markets to
discriminate on the basis of predictive neuroscience information.
Once this gap has been identified, Part IV will then explain why the gap is
problematic. It will focus on how the analogous nature of the information that
can be gleaned from each modality allows health insurers to get around
existing predictive genetic information discrimination protections afforded by
GINA and ACA, and why the incentive to do so is so strong. Indeed, predictive
neuroscience information may be even more deserving of protection than
genetic information due to its greater predictive reliability. A brief evaluation
of the number of people who could potentially be affected by this gap in
protection will further evidence the extent of the problem.
Finally, Part IV will propose potential ways to close this gap in order to
bring health insurance discrimination protections for predictive neuroscience
information in line with those of predictive genetic information. The easiest
and most practical solution would be to add a health-status-related factor in
ACA for predictive neuroscience information. Alternative solutions include
amending Title I of GINA to include predictive neuroscience information and
crafting new GINA-type legislation specifically for predictive neuroscience
information.
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I. THE GENETIC INFORMATION NONDISCRIMINATION ACT
A little over two decades ago, researchers were just beginning to
understand the human genome and the potential to harness the information it
could provide.11 As the value of this genetic information became evident, the
potential to unfairly discriminate based upon this information became equally
evident.12 These rapid genetic advances demonstrated the need for protective
legislation that would prohibit discriminatory uses of genetic information.13
This Part will discuss why GINA was enacted and examine the backdrop
against which it was enacted. This Part will then discuss the health insurance
antidiscrimination provisions found in Title I of GINA and their importance.
In 1990, the U.S. Department of Energy and the National Institutes of
Health founded the Human Genome Project as an international scientific
research project with the goal of mapping the entire human genome.14 The
project, which remains the largest collaborative biological project in history,15
was declared complete in April of 2003,16 when approximately 3 billion DNA
base pairs were sequenced and mapped.17 It was a staggering accomplishment
and revolutionized the fields of science, medicine, and health. This information
helped researchers understand diseases, allowed physicians to target their
therapies and interventions,18 contributed to the advance of forensic sciences,19
and aided the understanding of evolution,20 among other advances.
However, the implications of the Human Genome Project’s successful
completion were not all positive. There was widespread concern that this
11

See About the Human Genome Project, supra note 2.
COUNCIL FOR RESPONSIBLE GENETICS, GENETIC DISCRIMINATION: A POSITION PAPER (2001),
http://www.councilforresponsiblegenetics.org/pageDocuments/2RSW5M2HJ2.pdf.
13 See id.
14 See About the Human Genome Project, supra note 2.
15 Human Genome Project, WELLCOMETRUST, http://genome.wellcome.ac.uk/node30075.html (last
visited Apr. 27, 2015).
16 All About the Human Genome Project, NAT’L HUM. GENOME RES. INST., http://www.genome.gov/
10001772 (last updated Mar. 18, 2014).
17 U.S. Dep’t of Energy Human Genome Project, Major Events in the U.S. Human Genome Project and
Related Projects, HUMAN GENOME PROJECT INFO. ARCHIVE 1990–2003, http://web.ornl.gov/sci/techresources/
Human_Genome/project/timeline.shtml (last modified Jan. 22, 2015).
18 Human Genome Project, NAT’L INSTS. HEALTH, http://report.nih.gov/nihfactsheets/ViewFactSheet.
aspx?csid=45 (last updated Mar. 29, 2013).
19 Dragan Primorac, Human Genome Project-based Applications in Forensic Science, Anthropology, and
Individualized Medicine, 50 CROATIAN MED. J. 205, 205–06 (2009), available at http://www.ncbi.nlm.nih.gov/
pmc/articles/PMC2705009/pdf/CroatMedJ_50_0205.pdf.
20 Press Release, Univ. of Chi. Med. Ctr., Genome Project Opens the Book on Human Evolution
(Feb. 13, 2001), available at http://www.sciencedaily.com/releases/2001/02/010213081055.htm.
12
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genetic information would be used to discriminate against people in various
contexts, most notably in the employment and health insurance contexts.21
These concerns arose even before the project was completed, as demonstrated
by the introduction of the first version of a genetic antidiscrimination bill in the
House of Representatives and Senate in 1995.22 Over the next thirteen years,
many other versions of genetic antidiscrimination bills were subsequently
introduced in Congress.23 On May 21, 2008, President George W. Bush signed
GINA into law.24 GINA passed in the Senate by a vote of 95-to-0 and in the
House of Representatives 414-to-1, demonstrating the importance Congress
proscribed to protecting this newly acquired genetic information from
discriminatory misuse.25 Senator Ted Kennedy called GINA “the first civil
rights bill of the new century of the life sciences.”26
GINA has two main parts, affording specific protection from genetic
discrimination in the health insurance and employment contexts.27 Title I of
GINA pertains specifically to health insurance discrimination.28 Essentially, it
prevents health insurers from denying coverage or charging higher premiums
to a healthy person based solely on a genetic predisposition to disease.29 Title I
also prohibits health insurers from requesting or requiring genetic information
21 See Genetic Discrimination in Health Insurance or Employment, NAT’L HUM. GENOME RES. INST.,
http://www.genome.gov/11510227 (last reviewed Feb. 28, 2012).
22 See Genetic Nondiscrimination Federal Legislation Archive, NAT’L HUM. GENOME RES. INST.,
http://www.genome.gov/11510239 (last reviewed Mar. 17, 2014) (listing genetic antidiscrimination bills
introduced in the House of Representatives and Senate).
23 See id.
24 Remarks on Signing the Genetic Information Nondiscrimination Act of 2008, 44 WEEKLY COMP.
PRES. DOC. 736 (May 21, 2008).
25 See 154 CONG. REC. 7519–20 (2008) (recording vote of the House of Representatives); 154 CONG.
REC. 6841–42 (2008) (recording vote of the Senate).
26 Press Release, U.S. Senate Comm. on Health, Educ., Labor & Pensions, Kennedy, Enzi, Snowe
Celebrate Passage of Genetic Information Nondiscrimination Act (Apr. 24, 2008), available at
http://www.help.senate.gov/newsroom/press/release/?id=313bfde8-f967-46b4-aa9d-11bc73728813.
27 Since this Comment will focus on the health insurance context, it will not go into the employment
discrimination provisions embodied in Title II, which essentially prevent employers from basing job-related
employment decisions on individuals’ genetic information. See Genetic Information Nondiscrimination Act of
2008, Pub. L. No. 110-233, tit. II, 122 Stat. 881, 905–20 (codified at 42 U.S.C. §§ 2000ff to 2000ff-11 (2012));
OFFICE OF MGMT. & BUDGET, EXEC. OFFICE OF THE PRESIDENT, STATEMENT OF ADMINISTRATION POLICY:
H.R. 493 – GENETIC INFORMATION NONDISCRIMINATION ACT OF 2007 [hereinafter GINA STATEMENT OF
ADMINISTRATIVE POLICY], available at http://www.genome.gov/Pages/PolicyEthics/GeneticDiscrimination/
SAPonHR493.pdf.
28 Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, tit. I, 122 Stat. 881, 883–
905 (codified as amended in scattered sections of the Internal Revenue Code and Titles 29, 42 of the United
States Code).
29 See GINA STATEMENT OF ADMINISTRATIVE POLICY, supra note 27.
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or genetic testing, acquiring or using genetic information for medical
underwriting purposes, and treating genetic information as a preexisting
condition.30
Some individuals who undergo genetic testing may find out that they have
a higher probability of developing a disease. GINA is a very important
protection because without it, these individuals would not be protected from
discrimination by health insurers, who are always incentivized to charge more
to those with greater likelihood than the normal healthy population of requiring
medical care and services.31 Given the imperfect nature of predictive
information, many with predispositions to diseases would never actually
develop those diseases.32 For example, individuals carrying a BRCA gene
mutation have an increased risk for developing breast cancer, but the existence
of this mutation does not guarantee that person will ever actually develop
cancer or when; it just indicates that they are at greater risk for developing
cancer than an individual without the mutation.33 Additionally, the federal
government currently exercises limited oversight over the validity and
accuracy of existing genetic tests, making it even more difficult to ascertain the
information’s meaning and whether it is being interpreted correctly.34
Allowing discrimination on the basis of this imperfect information would
result in many people being penalized for a condition that may never
develop.35

30 See FAQs on the Genetic Information Nondiscrimination Act, U.S. DEP’T OF LABOR
http://www.dol.gov/ebsa/faqs/faq-GINA.html (last visited Apr. 27, 2015).
31 See supra note 9 and accompanying text.
32 See BRCA1 and BRCA2: Cancer Risk and Genetic Testing, NAT’L CANCER INST.,
http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA (last reviewed Apr. 1, 2015) (explaining that not all
women with a genetic predisposition to breast cancer actually develop the disease).
33 See id.
34 See Gail H. Javitt & Kathy Hudson, Federal Neglect: Regulation of Genetic Testing, ISSUES SCI. &
TECH., Spring 2006, at 59, available at http://www.unz.org/Pub/PolicyArchive-2006jan-00016?View=PDF.
35 See BRCA1 and BRCA2: Cancer Risk and Genetic Testing, supra note 32. Furthermore, allowing
health insurers to discriminate on the basis of this predictive information, even if it were perfect, would result
in unfair discrimination on the basis of an immutable characteristic over which these individuals have no
control. Existing antidiscrimination laws and Supreme Court jurisprudence suggest that this type of
discrimination is impermissible and that these characteristics are strongly deserving of protection. See Sharona
Hoffman, The Importance of Immutability in Employment Discrimination Law, 52 WM. & MARY L. REV. 1483
(2011); Jeffrey S. Morrow, Note, Insuring Fairness: The Popular Creation of Genetic Antidiscrimination,
98 GEO. L.J. 215 (2009); J. Atsu Amegashie, A Positive Theory of Immutable Characteristics and
Discrimination (Mar. 4, 2009) (unpublished manuscript), available at http://www.uoguelph.ca/~jamegash/
tolerable_discrimination.pdf. This Comment assumes that discrimination on the basis of immutable
characteristics is improper.
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GINA’s passage had a huge impact on the health insurance
antidiscrimination landscape. It was a unique law in that it sought to preempt
discrimination, rather than address it ex post facto, as the majority of
antidiscrimination laws typically do.36 As such, it is difficult to know whether
genetic discrimination would have become a reality. Given the strong financial
incentives for insurers to discriminate, however, it is reasonable to infer that it
would have.37 In any case, Congress acted nearly unanimously in response to
what it perceived as a real threat.38 Such action provides a glimpse into the
environment in which GINA was passed.
A major goal of GINA was to encourage continued biological and genetic
research.39 Given the potential for beneficial applications of genetic
information across myriad disciplines, it was generally thought that GINA-type
legislation would be necessary for people to feel more comfortable availing
themselves of existing genetic tests, both for the advancement of research
generally and individual diagnostic purposes.40 In this same vein, the growth of
personalized medicine depends upon individuals feeling comfortable obtaining
genetic tests for the purpose of crafting individualized medical approaches and
developing personalized therapies.41 The Coalition for Genetic Fairness also
postulated that since all humans inevitably would have some genetic
anomalies, it was necessary to protect genetic information from misuse
because it would provide an unfounded and unfair basis for discrimination.42
However, others argued that there was no demonstrated need for legislation
like GINA.43 They claimed there was no widespread showing of genetic
discrimination because it had only recently become possible to interpret and
make use of genetic information.44 These opponents disagreed with GINA’s
preemptive nature and supported a wait-and-see approach, believing GINA to
be overly broad in its protections because it would be impossible to know with
any certainty what provisions would be necessary without first seeing what
36

See Roberts, supra note 4, at 441.
See supra note 9 (discussing medical underwriting).
38 See supra note 25 and accompanying text.
39 See Roberts, supra note 4, at 471–74.
40 Id.
41 See David Resnick, GINA—A Big Step Toward Personalized Medicine, BOS. BUS. J. (Aug. 21, 2008,
6:04 PM EDT), http://www.bizjournals.com/boston/blog/mass-high-tech/2008/08/gina--a-big-step-towardpersonalized-medicine.html.
42 See The History of GINA, COALITION FOR GENETIC FAIRNESS, http://www.geneticfairness.org/
ginaresource_history.html (last updated Nov. 10, 2008) (describing several justifications for passing GINA).
43 Roberts, supra note 4, at 469–70.
44 See id.
37
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issues would arise on the genetic-discrimination front.45 In contrast, other
advocates argued that GINA didn’t go far enough in its protections because it
did not prevent genetic discrimination by life insurers, disability insurers, and
long-term care insurers.46 Another limitation in GINA’s protections is that they
cease once a genetic condition is manifest.47 Despite arguments against its
passage, GINA was important because it expanded existing protections to
include genetic information in an age where the availability of this information
and the role it played was becoming increasingly prevalent.
II. ADDITIONAL EXISTING HEALTH INSURANCE DISCRIMINATION
PROTECTIONS
In addition to Title I of GINA, which prevents health insurers from
discriminating on the basis of genetic information,48 there are many other laws
that protect against health insurance discrimination. This Part will discuss a
few of the major federal laws protecting against health insurance
discrimination to paint a fuller picture of the existing landscape of health
insurance discrimination protections.
A. Health Insurance Portability and Accountability Act
The Health Insurance Portability and Accountability Act of 199649
represents one of the most significant federal laws addressing health insurance
discrimination. HIPAA was the first piece of legislation in which the federal
government addressed health insurance discrimination and sought to afford
protections against it.50 One of the major rationales behind HIPAA’s passage
was to eliminate discrimination on the basis of an individual’s health status
and, more specifically, discrimination against individuals with preexisting
conditions.51 Before HIPAA, health insurers could freely deny coverage, limit

45

See id.
See Genetic Information Nondiscrimination Act of 2008, NAT’L HUM. GENOME RES. INST.,
http://www.genome.gov/10002328 (last updated Apr. 6, 2015).
47 Anya E. R. Prince & Benjamin E. Berkman, When Does an Illness Begin: Genetic Discrimination and
Disease Manifestation, 40 J.L. MED. & ETHICS 655, 655 (2012).
48 GINA STATEMENT OF ADMINISTRATIVE POLICY, supra note 27.
49 Pub. L. No. 104-191, 110 Stat. 1936 (codified as amended in scattered sections of the Internal Revenue
Code, and Titles 29 and 42 of the United States Code).
50 Jessica L. Roberts, “Healthism”: A Critique of the Antidiscrimination Approach to Health Insurance
and Health-Care Reform, 2012 U. ILL. L. REV. 1159, 1178.
51 See FAQs About Portability of Health Coverage and HIPAA, U.S. DEP’T OF LABOR,
http://www.dol.gov/ebsa/faqs/faq_consumer_hipaa.html (last visited Apr. 27, 2015).
46
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coverage, or charge exorbitant premiums for individuals with preexisting
medical conditions.52 HIPAA limited the circumstances in which health
insurers were permitted to consider such preexisting conditions in determining
eligibility for coverage and the extent and pricing of that coverage.53
However, HIPAA’s antidiscrimination provisions applied only to group
health insurance plans, typically obtained through an employer.54 This left
those without access to group health plans unprotected, which could be
problematic for many with preexisting conditions because they were unable to
obtain any meaningful coverage in the individual health insurance market.55
Furthermore, while HIPAA required group health insurance plans to provide
coverage for individuals with preexisting conditions, it both failed to provide
any provisions specifying what must be included in that coverage and failed to
cap the premiums at a reasonable rate.56
Although HIPAA was a step in the right direction toward limiting health
insurance discrimination, there were still many loopholes through which health
insurers might consider an individual’s health status and preexisting
conditions57 because HIPAA’s antidiscrimination provisions only applied to
group health insurance plans, not to individual health insurance plans.58 And
even among the discrimination protections provided in the group health
insurance market, protections preventing health insurers from providing weak
coverage or charging high premiums on the basis of preexisting conditions
were notably absent.59
52

See id.
See id.
54 See HIPAA, NAT’L MULTIPLE SCLEROSIS SOC’Y, http://www.nationalmssociety.org/living-withmultiple-sclerosis/insurance-and-money-matters/health-insurance/hipaa/index.aspx (last visited Apr. 27, 2015).
55 See Mary Crossley, Discrimination Against the Unhealthy in Health Insurance, 54 U. KAN. L. REV.
73, 84 (2005) (“Although the number of persons who obtain coverage through the individual market is
relatively small, the stakes are typically high, for purchasers in the individual market may have no other
coverage option.”).
56 See 29 U.S.C. § 1182(a)(2) (2012) (explaining that HIPAA should not be construed “(A) to require a
group health plan, or group health insurance coverage, to provide particular benefits other than those provided
under the terms of such plan or coverage, or (B) to prevent such a plan or coverage from establishing
limitations or restrictions on the amount, level, extent, or nature of the benefits or coverage for similarly
situated individuals enrolled in the plan or coverage”); id. § 1182(b)(2) (“Nothing in paragraph (1) shall be
construed—(A) to restrict the amount that an employer may be charged for coverage under a group health
plan . . . or (B) to prevent a group health plan, and a health insurance issuer offering group health insurance
coverage, from establishing premium discounts or rebates or modifying otherwise applicable copayments or
deductibles in return for adherence to programs of health promotion and disease prevention.”).
57 See supra notes 54–56 and accompanying text.
58 See supra note 56.
59 See supra note 56.
53
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B. Patient Protection and Affordable Care Act
Another major federal health insurance antidiscrimination law is the Patient
Protection and Affordable Care Act, which was signed into law in 2010 by
President Barack Obama.60 ACA has been characterized as a “civil rights bill
for the sick”61 and “represents the most significant regulatory overhaul of the
country’s healthcare system since the passage of Medicare and Medicaid in
1965.”62
ACA expands HIPAA’s discrimination protections in several key ways.
First, ACA includes guaranteed issue and renewal provisions, which foreclose
health insurers from discriminating at all when deciding whom to accept for
coverage.63 Health insurers now have no option but to accept everyone who
applies and continue that coverage until the insured wishes to terminate it.64
Second, ACA expands HIPAA’s protections by including both group
health plans and individual health plans in its prohibition against the
consideration of preexisting conditions65 when determining eligibility or
coverage, thereby imposing preexisting-condition restrictions on everyone.66
Third, ACA adopts and builds upon HIPAA’s idea of health status by
broadly imposing a prohibition on discrimination on the basis of health status
under both group health plans and individual health plans.67 ACA sets forth
nine health-status-related factors and prohibits health insurance discrimination
on the basis of any of those factors.68 The factors are (1) health status,
60 See Remarks on Signing the Patient Protection and Affordable Care Act, 2010 DAILY COMP. PRES.
DOC. 196 (March 23, 2010).
61 Lee-Lee Prina, Health Reform: What Foundations Are Saying and Funding, HEALTH AFF.
GRANTWATCH BLOG (Apr. 9, 2010), http://healthaffairs.org/blog/2010/04/09/health-reform-what-foundationsare-saying-and-funding/?cat=grantwatch.
62 Frequently Asked Questions about FASD, FETAL ALCOHOL SPECTRUM DISORDERS CTR. FOR
EXCELLENCE, http://fasdcenter.samhsa.gov/aboutUs/aboutFASD.aspx (last updated Apr. 17, 2015).
63 42 U.S.C. §§ 300gg-1(a) to (b), 300gg-2(a) (2012).
64 Id.
65 See Lisa Smith, Health Insurance: Paying for Pre-Existing Conditions, INVESTOPEDIA,
http://www.investopedia.com/articles/pf/09/covering-medical-costs.asp (last visited Apr. 27, 2015) (“Most
insurance companies use one of two definitions to identify such conditions. Under the ‘objective standard’
definition, a pre-existing condition is any condition for which the patient has already received medical advice
or treatment prior to enrollment in a new medical insurance plan. Under the broader, ‘prudent person’
definition, a pre-existing condition is anything for which symptoms were present and a prudent person would
have sought treatment.”).
66 See 42 U.S.C. § 300gg-3(a).
67 Id. § 300gg-4(a).
68 Id.
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(2) medical condition, (3) claims experience, (4) receipt of health care,
(5) medical history, (6) genetic information, (7) evidence of insurability,
(8) disability, and (9) any other health-status-related factor determined
appropriate by the Secretary of Health and Human Services.69
Finally, with respect to individual health plans and small-group health
plans of up to fifty enrollees,70 ACA allows health insurers to consider only
four criteria in determining what premiums to charge: (1) whether the
insurance coverage is for an individual or for a family, (2) what geographic
location or area the enrollee is in, (3) the enrollee’s age, and (4) whether the
enrollee uses tobacco products.71 This provision strongly limits health insurers’
discretion in setting premiums and eliminates many bases for discrimination.
The existing federal health insurance discrimination protections have been
steadily increasing with the passage of HIPAA in 1996,72 GINA in 2008,73 and
ACA in 2010.74 A critical distinction exists between a preexisting condition,
which is considered to be “anything for which symptoms [are] present and a
prudent person would have sought treatment,”75 and predictive information,
which necessarily presents itself prior to the onset of symptoms. The current
federal health insurance discrimination protections fail to address this
predictive information outside the genetic realm. This failure presents a critical
gap in discrimination protections in the health insurance arena as it pertains to
certain kinds of predictive health information, such as predictive neuroscience
information.
III. THE EMERGENCE OF PREDICTIVE NEUROSCIENCE
Neuroscience research has advanced rapidly, and the information that
scientists have been able to glean from these advances has fostered growth
with applications in many fields of study.76 The emerging ability to predict
disease with neuroscience techniques represents one of the most exciting of

69

Id.
A small-group health plan is typically sponsored by an employee and is defined to be a health plan
covering up to fifty enrollees. Consumer Guide to Group Health Insurance, NAT’L ASS’N OF HEALTH
UNDERWRITERS, http://www.nahu.org/consumer/GroupInsurance.cfm (last visited Apr. 27, 2015).
71 42 U.S.C. § 300gg(a)(1)(A).
72 See supra note 49 and accompanying text.
73 See supra note 24 and accompanying text.
74 See supra note 60 and accompanying text.
75 Smith, supra note 65.
76 See supra note 5.
70
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these advances.77 Similar to genetic advances, which received protection with
the passage of GINA in 2008,78 these neuroscience advances also need to be
protected to prevent health insurers from improperly using this information to
discriminate. This Part will discuss the emergence of predictive neuroscience
information and how health insurers can use this information to unfairly
discriminate.
The past twenty years have seen rapid and exciting advances in the field of
neuroscience. Neuroscience, the scientific study of the nervous system, has
countless applications that have the potential to revolutionize the way we think
about everything from disease to criminal culpability to bias detection.79
President George H. W. Bush “designat[ed] the 1990s as the Decade of the
Brain ‘to enhance public awareness of the benefits to be derived from brain
research.’”80 As a part of this project, the Library of Congress and the National
Institute of Mental Health partnered to sponsor various activities and
publications to foster and encourage brain research and increase public
awareness of the implications of these emerging neuroscience discoveries and
advances.81
More recently, this continuing commitment to fostering neuroscience
research spawned many interdisciplinary research undertakings. In 2013, the
Human Brain Project launched.82 This project is intended to be a ten-year
European research initiative with the goal of better understanding how the
brain functions through the simulation of the human brain with
supercomputers.83 The project recognizes the valuable insights that can be
gained through neuroscience advances and seeks to harness this information to
benefit research in the fields of neuroscience, medicine, and computing.84

77

For example, Alzheimer’s disease can be predicted through neuroimaging of amyloid plaques in the
brain. See Eric Karran, Marc Mercken & Bart De Strooper, The Amyloid Cascade Hypothesis for Alzheimer’s
Disease: An Appraisal for the Development of Therapeutics, 10 NATURE REVS. DRUG DISCOVERY 698 (2011),
available at http://www.nature.com/nrd/journal/v10/n9/pdf/nrd3505.pdf; Press Release, Perelman School of
Med. at the Univ. of Pa., supra note 6.
78 See supra note 24.
79 See Erickson, supra note 5; Tetlock et al., supra note 5.
80 Project on the Decade of the Brain, LIBR. CONG. (Jan. 3, 2000), http://www.loc.gov/loc/brain/.
81 Id.
82 See HBP Summit 2013: Overview, HUM. BRAIN PROJECT, https://www.humanbrainproject.eu/hbpsummit-2013-overview (last visited Apr. 27, 2015).
83 See Overview, HUM. BRAIN PROJECT, https://www.humanbrainproject.eu/discover/the-project/
overview (last visited Apr. 27, 2015).
84 See id.
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On April 2, 2013, the Obama administration proposed a similar
collaborative research initiative in the United States with the goal of mapping
the activity of every neuron in the human brain.85 The Brain Research through
Advancing Innovative Neurotechnologies Initiative (BRAIN Initiative), also
known as the Brain Activity Map Project, is based upon the Human Genome
Project,86 seemingly signaling the beginning of an era of neuroscience
advances similar to the era of genetic advances that took place in the 1990s and
early 2000s.87
One of the most practical applications of this growth in neuroscience
research lies in the areas of medicine and health. In particular, the emergence
of neuroscience as a modality to predict disease onset before any symptoms
manifest is a powerful tool for researchers and has the potential to
revolutionize how we approach and treat disease.88 In some cases, outcomes
may be significantly improved through early or preventative treatment,
favorably altering the course of the disease entirely.89 Additionally, predictive
neuroscience advances may help medical professionals identify how diseases
will react to certain treatments and allow for treatments to be tailored to
produce the best outcomes.90 Because health and medicine have the potential
to affect everyone, the importance and application of predictive neuroscience
advances are widespread.
One of the most promising advances in predictive neuroscience has been in
the field of Alzheimer’s disease research. Alzheimer’s disease is the most
common form of dementia, accounting for sixty to eighty percent of all

85 See OFFICE OF THE PRESS SEC’Y, THE WHITE HOUSE, FACT SHEET: BRAIN INITIATIVE (2013),
http://www.whitehouse.gov/the-press-office/2013/04/02/fact-sheet-brain-initiative.
86 See supra Part I.
87 See John Markoff, Obama Seeking to Boost Study of Human Brain, N.Y. TIMES, Feb. 18, 2013, at A1,
available at http://www.nytimes.com/2013/02/18/science/project-seeks-to-build-map-of-human-brain.html.
88 See, e.g., Biomarkers Can Predict Risk for Alzheimer’s Several Years Before Symptoms Appear, NAT’L
INST. ON AGING (June 15, 2013), http://www.nia.nih.gov/newsroom/announcements/2013/06/biomarkers-canpredict-risk-alzheimers-several-years-before-symptoms.
89 See Press Release, Am. Inst. of Physics, Detecting Alzheimer’s Early: Optical Scientists, Psychiatrists
Develop Minimally Invasive Eye Test for Alzheimer’s (Dec. 1, 2005), available at
https://retainyourmindfulness.wordpress.com/2011/05/24/sciencedaily-your-source-for-the-latest-researchnews-and-science-breakthroughs-updated-daily-science-video-share-blog-print-bookmark-email-detectingalzheimers-early-optical-scientists-p/ (“If we can get treatments early . . . we can slow the disease to the point
where we’ve effectively cured it.”).
90 See James Woolley & Philip McGuire, Neuroimaging in Schizophrenia: What Does It Tell the
Clinician?, 11 ADVANCES PSYCHIATRIC TREATMENT 195, 197–99 (2005), available at http://apt.rcpsych.org/
content/11/3/195.full.pdf.
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dementia cases.91 It is a progressive disease that gradually worsens, and it is
the sixth leading cause of death in the United States, indicating a high societal
disease burden.92 Although currently there is no cure for Alzheimer’s disease,
the ability to predict it could have important implications in terms of preparing
patients and their families, especially since the affected patient will eventually
become dependent on his or her caretakers.93 One of the prevailing theories
behind Alzheimer’s disease is the amyloid hypothesis, which proposes that
beta-amyloid deposits in the brain fundamentally cause the disease.94
Neuroimaging has allowed researchers to view the buildup of amyloid plaques
in the brain, which may predict the onset of Alzheimer’s disease.95
Additionally, the analysis of cerebrospinal fluid (CSF), found around and
inside the brain and spinal cord, may also serve a predictive function since the
amyloid fragments that make up brain plaques are also present and can be
identified in CSF.96 Research has shown that these biomarkers are very good
predictors for identifying which patients will develop cognitive impairment
and how soon the impairment will set in,97 though it is important to note that
these predictions are far from perfect.98
Another Alzheimer’s disease development on the horizon is the use of a
simple, noninvasive eye test to detect changes in the widths of certain blood
vessels in the retina, which correspond to the amount of plaque buildup in the
brain.99 An eye test would be far less expensive than a brain scan and could
91

See What Is Alzheimer’s?, ALZHEIMER’S ASS’N, http://www.alz.org/alzheimers_disease_what_is_
alzheimers.asp (last visited Apr. 27, 2015).
92 See id.
93 See, e.g., Paula Spencer Scott, What is Alzheimer’s Disease, CARING, https://www.caring.com/articles/
alzheimers-disease (last visited Apr. 27, 2015).
94 See Karran et al., supra note 77.
95 PET scans are the most common form of neuroimaging used to detect amyloid plaque buildup in the
brain. See Press Release, Am. Acad. of Neurology, supra note 6; Press Release, Perelman School of Med. at
the Univ. of Pa., supra note 6.
96 Geert De Meyer et al., Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively
Normal Elderly People, 67 ARCHIVES NEUROLOGY 949, 951 (2010).
97 See supra notes 95–96.
98 While predictive biomarkers show great promise, they are not perfect predictors of disease. Some
people who exhibit brain scans that would seem to indicate the extensive presence of a disease biomarker
function perfectly well and will never develop the disease, while others with scans showing identical
biomarker levels are very impaired. See Richard Mayeux, Biomarkers: Potential Uses and Limitations,
1 NEURORX 182, 186 (2004), available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC534923/pdf/
neurorx001000182.pdf.
99 See Press Release, Cognoptix, Cognoptix Drug/Device Test Identifies Alzheimer’s Disease via Beta
Amyloid Signature in the Eyes in a 10-Subject Proof-of-Concept Trial (Jan. 3, 2013), available at
http://www.businesswire.com/news/home/20130103005076/en/Cognoptix-DrugDevice-Test-IdentifiesAlzheimer%E2%80%99s-Disease-Beta#.UwFFxUJdX68; Press Release, supra note 89.
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serve as a more accessible tool for Alzheimer’s disease prediction in the near
future.100 These studies suggest that researchers may now have the ability to
detect and predict the onset of Alzheimer’s disease years before any symptoms
of memory loss or cognitive decline manifest.101 And there is evidence to
support that predictive neuroscience advances in the field of Alzheimer’s
disease may even have greater predictive value than the corresponding genetic
test, which hints at exciting research opportunities.102
Neuroscience advances that predict other neurodegenerative diseases, such
as Huntington’s disease and Parkinson’s disease, are following in the footsteps
of Alzheimer’s disease research, and it may soon be possible to use
neuroscience techniques to predict their onset before symptoms manifest as
well. Preliminary studies indicate that individuals with Huntington’s disease
may have measurable characteristics indicating decline before actual diagnosis
and symptom onset occur.103 For example, current predictive research for
Huntington’s disease indicates that magnetic resonance imaging (MRI)
measurement of gray-matter volume in the brain has shown promise in
predicting the clinical diagnosis of Huntington’s disease before symptom
onset.104
Similarly, neuroscience advances may soon contribute to the prediction of
Parkinson’s disease onset and progression. Currently, it is not possible to
predict the onset or progression of Parkinson’s with any certainty.105 However,
neuroimaging has provided evidence of decreased volume in the cortex of the
100

See Press Release, supra note 99.
However, Alzheimer’s disease has no known cure, so early detection would only help prepare the
individual and their family for what is to come, but wouldn’t be able to prevent it. See Michael C. Purdy,
Alzheimer’s Markers Predict Start of Mental Decline, WASH. UNIV. ST. LOUIS NEWSROOM (May 13, 2013),
https://news.wustl.edu/news/Pages/25412.aspx.
102 A brain scan for amyloid plaques is a better predictor of Alzheimer’s disease than getting a genetic
test. Brain Plaque vs. Alzheimer’s Gene, CHI. TRIB., Sept. 29, 2013, http://articles.chicagotribune.com/201309-29/lifestyle/sns-201302191850--tms--harvhltl69l0313e-20130219_1_apoe4-brain-scan-alzheimer.
103 Nat’l Insts. of Health, Neurobiological Predictors of Huntington’s Disease (PREDICT-HD),
CLINICALTRIALS, http://clinicaltrials.gov/show/NCT00051324 (last updated Dec. 4, 2014).
104 See Jan Kassubek et al., Thalamic Atrophy in Huntington’s Disease Co-varies with Cognitive
Performance: A Morphometric MRI Analysis, 15 CEREBRAL CORTEX 846 (2005), available at http://cercor.
oxfordjournals.org/content/15/6/846.full.pdf+html; see also Mario Quarantelli et al., Default-Mode Network
Changes in Huntington’s Disease: An Integrated MRI Study of Functional Connectivity and Morphometry,
8 PLOS ONE, no. 8, art. no. 72159, 2013, at 1, http://www.plosone.org/article/fetchObject.action?uri=info
%3Adoi%2F10.1371%2Fjournal.pone.0072159&representation=PDF; D. Stoffers et al., Contrasting Gray and
White Matter Changes in Preclinical Huntington’s Disease: An MRI Study, 74 NEUROLOGY 1208 (2010),
available at http://www.aronlab.org/Pubs/Stoffers_Neurology.pdf.
105 See Karen Weintraub, Researchers Take Step Toward Predicting Parkinson’s, USA TODAY, Aug. 26,
2013, http://www.usatoday.com/story/news/nation/2013/08/26/parkinsons-predictor/2701019/.
101
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brain and decreased resting metabolic activity that appear prior to the onset of
Parkinson’s dementia.106 Additionally, biomarkers found in the CSF show
promise in predicting Parkinson’s onset and the severity of motor
dysfunction.107 Though further research is necessary, it may soon be possible
to use neuroimaging and CSF biomarkers to predict the onset and progression
of cognitive impairment and motor dysfunction in Parkinson’s patients.
In addition to predictive implications for neurodegenerative diseases,
neuroscience advances also have predictive implications for psychotic mental
disorders, such as schizophrenia. There is compelling evidence from
neuroimaging to suggest that schizophrenia is a brain disease.108 Neuroimaging
techniques have highlighted structural brain changes that appear to be
correlated with the symptoms of schizophrenia, including enlargement of the
lateral ventricles in the brain, undersized temporal lobe volume, and prefrontal
lobe abnormalities.109 Additionally, functional magnetic resonance imaging
(fMRI) studies, which measure brain activity as opposed to brain structure,110
suggest that brain activity in response to certain cognitive demands may appear
different for at-risk individuals.111 These advances may make it possible to
predict disease course, response to treatment, and potential for relapse.112
Neuroimaging has the potential to elucidate much in the mental-illness sphere
in particular because currently, psychiatric disorders, such as schizophrenia,
are diagnosed solely via symptom-based diagnostic criteria.113 If reliable and
identifiable structural or functional brain changes can be correlated with
schizophrenia symptoms and onset, it follows that neuroimaging may make it

106 See Lisa C. Silbert & Jeffrey A. Kaye, Neuroimaging and Cognition in Parkinson’s Disease Dementia,
20 BRAIN PATHOLOGY 646 (2010), available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327506/.
107 See Jian Wang et al., Biomarkers of Parkinson’s Disease: Current Status and Future, 18 DRUG
DISCOVERY TODAY 155, 159, 160 nn.3–4.
108 See Peter F. Buckley, Neuroimaging of Schizophrenia: Structural Abnormalities and
Pathophysiological Implications, 1 NEUROPSYCHIATRIC DISEASE & TREATMENT 193, 202 (2005), available at
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2416751/pdf/ndt-0103-193.pdf.
109 See
Shawn
J.
Kile,
Neuropsychiatric
Update:
Neuroimaging
Schizophrenia,
40 PSYCHOPHARMACOLOGY BULL. 156 (2007).
110 What Is fMRI?, CTR. FOR FUNCTIONAL MRI, http://fmri.ucsd.edu/Research/whatisfmri.html (last
visited Apr. 27, 2015).
111 See Paul C. Fletcher, Editorial, Functional Neuroimaging of Schizophrenia: From a Genetic
Predisposition to the Emergence of Symptoms, 127 BRAIN 457, 457 (2004), available at http://brain.
oxfordjournals.org/content/127/3/457.full.pdf+html.
112 See Woolley & McGuire, supra note 90, at 197–99.
113 See AM. PSYCHIATRIC ASS’N, DSM-5: DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL
DISORDERS 87 (5th ed. 2013).
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possible to predict schizophrenia before any of these diagnostic symptoms
manifest.
Another predictive neuroscience application on the horizon relates to
multiple sclerosis (MS). MS affects as many as 2.5 million people throughout
the world and is the most common cause of progressive disability found in
young adults.114 MS is a disease where the body attacks the central nervous
system of the patient.115 As a result of this attack, myelin, the protective tissue
that surrounds the nerve cells of the brain, spinal cord, and optic nerves, is
damaged.116 Neuroimaging technologies are helping researchers make strides
toward the prediction of MS through the discovery of visible differences in
gray matter in the brain that correlate with the disease, which are detectable in
the very earliest stages of MS.117 Although MS research initially focused on
white matter, MRI technology has enabled researchers to better visualize gray
matter, and it has become clear that gray matter pathology plays an important
role in the development of MS.118 Studies have shown that gray matter atrophy
in the thalamus of the brain has been associated with MS.119 According to one
researcher, “[t]halamic atrophy is an ideal MRI biomarker because it’s
detectable at a very early stage . . . . It has very good predictive value.”120
Additionally, MRI studies have shown that darker gray matter, suggestive of
increased iron deposits, may be another biomarker for MS, which may allow
physicians to more accurately identify patients at risk for developing the
disease.121 Given the rapid advances in MS research with the help of MRI
technology, it may soon be possible to predict who will develop MS prior to
any symptom onset.
114 Press Release, Wiley, Multiple Sclerosis Progression Can Be Predicted With MRI (Nov. 5, 2008),
available at http://www.eurekalert.org/pub_releases/2008-11/w-msp110508.php.
115 Definition of MS, NAT’L MULTIPLE SCLEROSIS SOC’Y, http://www.nationalmssociety.org/aboutmultiple-sclerosis/what-we-know-about-ms/what-is-ms/index.aspx (last visited Apr. 27, 2015).
116 Id.
117 See Justin Morris Honce, Gray Matter Pathology in MS: Neuroimaging and Clinical Correlations,
2013 MULTIPLE SCLEROSIS INT’L, art. no. 627870, at 1, http://www.hindawi.com/journals/msi/2013/627870/;
see also Elisabeth Andreadou, Neuroimaging in Multiple Sclerosis, in NEUROIMAGING—CLINICAL
APPLICATIONS 317 (Peter Bright ed., 2012), available at http://cdn.intechopen.com/pdfs/31418/InTechNeuroimaging_in_multiple_sclerosis.pdf; Nancy L. Sicotte, Neuroimaging in Multiple Sclerosis:
Neurotherapeutic Implications, 8 NEUROTHERAPEUTICS 54, 58 (2011), available at http://www.ncbi.nlm.nih.
gov/pmc/articles/PMC3075734/pdf/13311_2010_Article_8.pdf.
118 See Honce, supra note 117, at 1.
119 Carola Finch, MRI Can Predict Onset of Multiple Sclerosis, EXAMINER (Apr. 23, 2013, 8:53 PM
MST), http://www.examiner.com/article/mri-can-predict-onset-of-multiple-sclerosis; see Honce, supra
note 117, at 15.
120 Finch, supra note 119 (internal quotation marks omitted).
121 See Press Release, supra note 114.
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The recent emergence of this predictive neuroscience technology may soon
make it possible to predict a variety of diseases before their clinical onset.
Although only Alzheimer’s disease can currently be predicted with any relative
certainty using neuroimaging techniques, a great volume of research is being
done on many other diseases, which are following closely in the footsteps of
Alzheimer’s disease research in the search for predictive correlates that will
allow researchers to identify those who may develop diseases years before any
symptoms manifest. These health-related benefits raise exciting new
possibilities, but they are accompanied by costs because this predictive
information also has the potential to be the basis for unfair health-related
discrimination.
IV. THE NEED FOR PROTECTION FOR PREDICTIVE NEUROSCIENCE
INFORMATION
Predictive neuroscience information should be protected in the same way
that genetic information is protected under GINA and ACA from health
insurance discrimination. As predictive neuroscience advances become
increasingly part of the health and medical landscape, the potential to harness
this neuroscience information for good is countered by the potential to misuse
the information in order to unfairly discriminate against people based upon its
predictive value. This is problematic because while predictive information may
serve many useful purposes, it is far from perfect.122 The potential to
misinterpret and misuse predictive information is high, and as such, this
information deserves protection to ensure that health insurers do not unfairly
discriminate against those who undergo these predictive neuroscience tests.
This Part will discuss existing discrimination protections in greater depth,
with each provision narrowing the range of excluded areas from protection.
This analysis will show that after all the existing provisions and protections
have been applied and considered, there remains a narrow gap in the
discrimination protections where predictive neuroscience information in the
large-group and self-insured health insurance markets is still unprotected. After
identifying this gap in protection, this Part will discuss why this gap is
problematic and then conclude by suggesting potential ways to close this gap
by extending appropriate protection to predictive neuroscience information.

122

See Mayeux, supra note 98, at 186–87.
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A. A Gap in Existing Health Insurance Antidiscrimination Provisions
This section will demonstrate that there is a gap in existing health insurance
discrimination protections by discussing various provisions of ACA. Each
provision will narrow the area excluded from protection. Once the applicable
protections have been applied, this section will show that there is still a small
area where predictive neuroscience information in the large-group and
self-insured health insurance markets is excluded. The following diagram is an
illustrative overview of the analysis:
FIGURE

Key
Guaranteed Issue and Guaranteed Renewal provisions: protect against all
enrollment discrimination but not against rate discrimination.
Preexisting Condition provision: protects against existing condition discrimination
but not against discrimination on the basis of any predictive information.
Health Status provision: protects against predictive genetic information
discrimination but not against predictive neuroscience information discrimination.
Rating Factors provision: prevents individual and small-group markets from
considering predictive neuroscience information in setting rates but doesn’t prevent
large-group and self-insured markets from considering the same information.
The gap: no protection from rate discrimination for predictive neuroscience
information in the large-group and self-insured markets.

1. Guaranteed Issue and Guaranteed Renewal
ACA’s protections are expansive and mark a significant step forward in
limiting health insurance discrimination. In particular, ACA’s guaranteed issue
and guaranteed renewal provisions ensure that health insurance will be
accessible to all and take away any opportunity for health insurers to
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discriminate in deciding who they will cover.123 These provisions apply to both
the individual and group markets, meaning that health insurers are required to
accept every employer and individual who applies for health insurance and
must renew that coverage at the insured’s election.124 This is important because
health insurers previously could discriminate in two main areas. First, they
could discriminate in deciding whom to accept for enrollment. Second, they
could discriminate in deciding what rates to charge those they had accepted for
enrollment and how extensive to make the coverage offered. ACA’s
guaranteed issue and guaranteed renewal provisions take away the discretion
of health insurers to discriminate in the first scenario since the provisions
require them to accept everyone who applies for enrollment and require that
the enrollment continue as long as the insured wishes.125 Consequently, the
opportunity for discrimination is now limited only to the second scenario, in
which health insurers discriminate by setting disparate rates for their enrollees.
2. Preexisting Conditions
Within this second scenario, ACA offers further discrimination protections
with its preexisting condition provision, which states that health insurers are
not permitted to impose any preexisting condition exclusions with respect to
the coverage they offer.126 A preexisting condition is “anything for which
symptoms were present and a prudent person would have sought treatment.”127
This definition makes clear that ACA’s preexisting condition protections only
extend to conditions after the onset of symptoms. This has the effect of
excluding any predictive information from ACA’s preexisting condition
protections since, by definition, predictive information applies when one does
not yet have a condition but, for one reason or another, has a greater likelihood
of developing a condition in the future. Accordingly, since health insurers are
not permitted to exclude existing conditions from coverage, ACA protects
those with existing conditions from discrimination based on their condition.128
However, the preexisting condition provision fails to address predictive
information since predictive information is clearly outside the definition of an
existing condition under ACA. So while the preexisting condition provision

123
124
125
126
127
128

See 42 U.S.C. §§ 300gg-1(a) to (b), 300gg-2(a) (2012).
Id.
Id.
See id. § 300gg-3(a).
Supra note 65 and accompanying text.
42 U.S.C. § 300gg-3.
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narrows the opportunity for health insurance discrimination by protecting those
with existing conditions, it leaves all predictive information unprotected.129
3. Health Status
A further protection afforded by ACA is the health status provision, which
prohibits health insurers from discriminating based on the health status of an
enrollee.130 This provision sets forth nine health-status-related factors:
(1) health status, (2) medical condition, (3) claims experience, (4) receipt of
health care, (5) medical history, (6) genetic information, (7) evidence of
insurability, (8) disability, and (9) any other health-status-related factor
determined appropriate by the Secretary of Health and Human Services.131
Currently, predictive health information can come in the form of genetic or
neuroscience information.132 However, the sixth ACA health-status-related
factor explicitly closes the door on health insurance discrimination on the basis
of any genetic information,133 seemingly in acknowledgment of Title I of
GINA, which was enacted two years prior to ACA.134 It appears that Congress
intended to embody and reinforce Title I of GINA, which prevents health
insurers from denying coverage or charging higher premiums to a healthy
person based solely on a genetic predisposition to developing a disease.135
Additionally, when read in light of ACA’s other provisions and taking into
consideration the explicit mention of genetic information as a
health-status-related factor,136 Congress actually expanded the scope of
existing genetic information protection markedly in the health insurance realm.
An important limitation of GINA prior to ACA was that its protections ceased
once a condition had become manifest.137 GINA defines manifest as any
condition that “could reasonably be detected by a health care professional with
appropriate training and expertise in the field of medicine involved.”138 This
limited GINA’s protections to predictive genetic information since once the
129

See id.
See id. § 300gg-4(a).
131 Id.
132 See supra Parts I and III for more detail on how genetic and neuroscience information can be used to
predict diseases.
133 42 U.S.C. § 300gg-4(a)(6).
134 GINA STATEMENT OF ADMINISTRATIVE POLICY, supra note 27.
135 See 42 U.S.C. § 300gg-3(a).
136 See id. § 300gg-4(a)(6).
137 See Prince & Berkman, supra note 47, at 655.
138 29 U.S.C. § 1191b(d)(7)(B)(ii) (2012).
130

SHIN GALLEYS PROOFS

1456

4/29/2015 1:21 PM

EMORY LAW JOURNAL

[Vol. 64:1433

condition had become manifest, that individual was no longer protected from
health insurance discrimination under GINA.
Interestingly enough, with the passage of the ACA, GINA’s once-critical
disease-manifestation line has seemingly been rendered irrelevant. The
definition of preexisting condition (“anything for which symptoms were
present and a prudent person would have sought treatment”)139 and manifest
condition (any condition that “could reasonably be detected by a health care
professional with appropriate training and expertise in the field of medicine
involved”)140 are almost analogous and provide a seamless transition from the
predictive genetic protections of GINA to the preexisting condition protections
of ACA. For example, if an individual has a genetic predisposition to
developing Alzheimer’s disease, under GINA, health insurers may not use this
information to unfairly discriminate against him or her in making coverage and
enrollment decisions or in setting his or her premium rates.141 Once the
Alzheimer’s disease “could reasonably be detected by a health care
professional with appropriate training and expertise in the field of medicine
involved,”142 GINA’s protections would cease. But ACA picks up where
GINA’s protections leave off, extending its preexisting condition protections to
that same individual with Alzheimer’s disease once “symptoms [are] present
and a prudent person would [seek] treatment.”143 It is difficult to imagine a
scenario in which an individual would lose GINA’s protections once his or her
condition has manifested and ACA’s preexisting condition protections
wouldn’t immediately take effect.
In effect, ACA’s previously discussed protections and GINA’s genetic
information protections demonstrate that there is a narrow gap where
predictive neuroscience information is the only information excluded from
protection from health insurance discrimination. In analyzing the other
health-status-related factors, it becomes clear that none address predictive
information. The first factor, health status, is very vague because it appears to
have no force of its own, as its definition is simply inclusive of the second
through the eighth factors.144 The second through the fifth factors, in addition
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See supra note 65 and accompanying text.
42 U.S.C. § 300gg-91(d)(17)(B)(ii).
141 29 U.S.C. § 1182(b)–(d); 42 U.S.C. §§ 300gg-1(b) to (c), (d)(19), 300gg-53(a) to (d).
142 42 U.S.C. § 300gg-91(d)(17)(B)(ii).
143 See supra note 65 and accompanying text.
144 See 42 U.S.C. § 300gg-4(a)(1); Health Status, HEALTHCARE.GOV, https://www.healthcare.gov/
glossary/health-status/ (last visited Apr. 27, 2015).
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to the eighth factor (medical condition, claims experience, receipt of health
care, medical history, and disability) do not have anything to do with
predictive information.145 And the sixth factor, genetic information, was
previously discussed.146 This leaves only the seventh factor, evidence of
insurability, to consider.147
Evidence of insurability has been interpreted under governmental guidance
from the U.S. Department of Labor to refer to “[c]onditions arising from acts
of domestic violence as well as participation in activities like motorcycling,
snowmobiling, all-terrain vehicle riding, horseback riding, and skiing.”148
When read in light of this guidance, it is clear that evidence of insurability does
not refer to predictive information. This lends itself to the conclusion that
while Title I of GINA and the sixth health-status-related factor protect
predictive genetic information,149 ACA’s health status provision does not
protect predictive neuroscience information from health insurance
discrimination.
4. Rating Factors
While ACA’s preexisting condition and health status provisions do not
protect predictive neuroscience information from health insurance
discrimination, ACA does protect a certain class of the insured through its
rating factors.150 For the individual and small-group markets, ACA permits
only four factors to be considered when health insurers set premium rates.151
These four rating factors are (1) whether the plan covers an individual or a
family, (2) the rating area, (3) age, and (4) tobacco use.152 This limitation
means that regardless of the fact that predictive neuroscience information is not
protected specifically from health insurance discrimination, ACA’s rating
factors prohibit health insurers from considering anything other than these four
factors when setting premium rates in the individual and small-group markets.
However, ACA’s rating factors specifically do not apply to the large-group and
145

See 42 U.S.C. § 300gg-4(a)(2) to (5), (8).
See supra note 133 and accompanying text.
147 See 42 U.S.C. § 300gg-4(a)(7).
148 FAQs About Portability of Health Coverage and HIPAA, supra note 51 (discussing HIPAA’s health
status factors, which were amended to reflect ACA’s protections and are based off of ACA’s health status
factors).
149 See supra notes 133, 141 and accompanying text.
150 42 U.S.C. § 300gg(a)(1)(A).
151 See id.
152 Id.
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self-insured markets, leaving predictive neuroscience information in those
groups unprotected.153
B. Why this Gap Is Problematic
As there are no further antidiscrimination provisions on point, a careful
analysis of the existing health insurance discrimination protections reveals a
narrow gap in protection for predictive neuroscience information in the
large-group and self-insured markets. This section will discuss why this gap is
significant and why it should be closed.
While the gap in protection appears narrow, it is a critical gap that requires
attention because a significant part of the overall insured population falls
within this gap. Employers who have over fifty employees most commonly
utilize large group plans.154 The ten largest employers in America in 2013
alone employed over 5.6 million employees,155 so it is not difficult to see that
many people could potentially be affected by this gap. In addition, the gap in
protection is problematic because, with the increasing availability of predictive
neuroscience technologies and information, it gives health insurers a way to
undercut the protections provided by GINA and ACA. Furthermore, if health
insurers are prohibited from discriminating on the basis of genetic information,
they are highly incentivized to turn to any alternative legal means of obtaining
the same information to serve the same purpose.156
1. Predictive Neuroscience Information Could Be Used to Undercut GINA
On the one hand, predictive neuroscience information is closely analogous
to predictive genetic information. Genetic advances and the power to harness
the information provided by such advances raised problems that ultimately
drove Congress to enact GINA.157 Many of those same problems are posed by
predictive neuroscience information with respect to discrimination. For
example, one of the most widespread considerations behind the passage of
GINA was the desire to encourage and advance scientific research and ensure
that individuals would feel comfortable availing themselves of genetic testing
153

See id.
See Small and Large Business Health Insurance: State & Federal Roles, NCSL, http://www.ncsl.org/
research/health/small-business-health-insurance.aspx (last updated Feb. 1, 2015).
155 Alexander E.M. Hess, The 10 Largest Employers in America, USA TODAY, Aug. 22, 2013,
http://www.usatoday.com/story/money/business/2013/08/22/ten-largest-employers/2680249/.
156 See supra note 9 and accompanying text.
157 See Roberts, supra note 4, at 471–74; Resnick, supra note 41; The History of GINA, supra note 42.
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without fear of that same helpful information being used against them in a
discriminatory manner.158 Identical considerations lend support to the
protection of predictive neuroscience information. As predictive neuroscience
technologies continue to advance, the use of this information will become
more common. But in order for research to take place, and targeted therapies
and earlier disease interventions to become a reality, subjects must be willing
to participate in studies that may reveal predictions about their disease
development in the future. And in order to find willing subjects, there must be
adequate protection for those subjects against misuse of the predictive
information gleaned from the research studies.
This same logic holds true for the encouragement of early predictive
neuroscience testing for early intervention purposes in individual patients. The
ability to predict a disease before any symptom onset facilitates research and
development of earlier treatments that may delay or minimize the harm
imposed by that disease on that individual.159 For example, Alzheimer’s
disease prediction before symptom onset could allow for future treatment to
target the disease before irreversible brain damage or mental decline occurs.160
While genetic information and predictive neuroscience information pose
many of the same problems, predictive neuroscience information is not
protected from health insurance discrimination. This protection gap is
problematic because, since genetic information and predictive neuroscience
information are analogous in many ways, it is possible for health insurers to
glean much of the same information from predictive neuroscience information
that they could get from genetic information.161 Since Title I of GINA prohibits
health insurers from requesting or requiring genetic information or genetic
testing, acquiring or using genetic information for medical underwriting
purposes, and treating genetic information as a preexisting condition,162 health
insurers may be incentivized to get around the antidiscrimination provisions of
GINA and find alternative ways of evaluating their risk in insuring
individuals.163 Health insurers could easily turn to other predictive
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See supra note 157.
See Cynthia A. Lemere & Eliezer Masliah, Can Alzheimer Disease Be Prevented by Amyloid-β
Immunotherapy?, 6 NATURE REVS. NEUROLOGY 109, 116 (2010).
160 See id.
161 See supra note 6 and accompanying text.
162 See 29 U.S.C. § 1182(c)(1), (d)(1)–(2) (2012).
163 See supra note 9 and accompanying text.
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technologies that are not specifically afforded the same protections as genetic
information to get roughly the same information.
For example, the apoE4 gene is the strongest risk gene known for
predicting Alzheimer’s disease and is implicated in about 20%–25% of all
Alzheimer’s cases.164 Under GINA, health insurers cannot ask whether a
patient has this form of the gene, require them to undergo testing for the gene,
or use information about the gene in making enrollment, coverage, or premium
decisions, as long as they do not yet exhibit symptoms sufficient for a
diagnosis of Alzheimer’s disease.165 However, it has recently become possible
to alternatively predict Alzheimer’s disease through neuroimaging of amyloid
plaques and analysis of amyloid fragments in the CSF.166 Because this
predictive neuroscience information is not afforded any protection against
health insurance discrimination in the large-group and self-insured markets,
health insurers could get around GINA’s protections by turning to predictive
neuroscience information that may tell them roughly the same thing. It is
crucial that this predictive neuroscience information be protected so health
insurers cannot render those genetic protections obsolete by merely
circumventing the protection and using roughly analogous predictive
neuroscience information as a substitute for the genetic information they are
prohibited from using.
2. Predictive Neuroscience Information Provides a Greater Incentive for
Abuse than Predictive Genetic Information
Although predictive neuroscience information is in many ways analogous
to genetic information, it is also unique and raises its own issues that merit
consideration. On the one hand, predictive neuroscience information, and
neuroimaging in particular, show structural and functional changes occurring
in the brain or elsewhere. These changes may be representative of disease in
the future if neuroscientists can develop strong enough and reliable enough
correlations between the neuroimaging information findings and future disease
onset.167 Once neuroscientists find a good biomarker, which can include
164

What We Know Today About Alzheimer’s Disease, supra note 6.
See supra notes 28–30.
166 See supra notes 95–96.
167 See Christopher J. Honey, Jean-Philippe Thivierge & Olaf Sporns, Can Structure Predict Function in
the Human Brain?, 52 NEUROIMAGE 766, 774 (2010), available at http://chialvo.org/Curso/UBACurso/
DIA9/Papers/HoneyStructureFunction.pdf; Alzheimer’s and Dementia Testing for Earlier Diagnosis,
ALZHEIMER’S ASS’N, http://www.alz.org/research/science/earlier_alzheimers_diagnosis.asp (last visited Apr.
27, 2015).
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anything from blood or spinal fluid proteins to brain changes visible through
imaging, and the biomarker has been validated, which means its predictive
value has been confirmed through studies, they can then use this predictive
information in a variety of health-related settings.168 However, it is unclear in
many cases what the relationship is between many of these identifiable
changes and disease manifestation.169 Researchers are constantly seeking to
elucidate how these visible neuroimaging changes may contribute to disease
and to determine whether they contribute to the cause of the disease or whether
they are effects of the underlying disease.170 Furthermore, once the biomarkers
are discovered and validated, additional research must be carried out to
determine the correlation’s reliability and to utilize the relationship between
the visible changes and the disease to benefit future research and treatment for
patients who may develop, or are currently living with, the disease.171 As
neuroscience research continues to advance and the pathology of diseases are
better understood, it is likely that predictive neuroscience information will get
swallowed into what is considered to be disease onset, allowing for earlier
detection of diseases. But until technology and research advance to that extent,
predictive neuroscience information can be very valuable on its own because it
shows actual identifiable changes occurring in the brain and elsewhere that are
predictive of disease onset in the future.172
On the other hand, genetic information is different because, in most
instances, it is not actually predictive of disease.173 It merely indicates that an
individual has a higher chance of getting a disease due to the genes he or she
possesses.174 Using genetic information to predict disease onset is very
168

Alzheimer’s and Dementia Testing for Earlier Diagnosis, supra note 167.
See Giuseppe Verdile et al., The Role of Beta Amyloid in Alzheimer’s Disease: Still a Cause of
Everything or the Only One Who Got Caught?, 50 PHARMACOLOGICAL RES. 397, 397 (2004), available at
http://ac.els-cdn.com/S104366180400091X/1-s2.0-S104366180400091X-main.pdf?_tid=98292002-464b11e3-9a5b-00000aacb35d&acdnat=1383677804_8f3e2d8ba040216ca574e38b192ba85d (explaining the debate
between Alzheimer’s researchers as to whether the beta-amyloid protein is a cause or an effect of the disease).
170 See id.
171 See Alzheimer’s and Dementia Testing for Earlier Diagnosis, supra note 167.
172 See Judy Illes & Matthew Kirschen, Editorial, New Prospects and Ethical Challenges for
Neuroimaging Within and Outside the Health Care System, 24 AM. J. NEURORADIOLOGY 1932 (2003).
173 There are exceptions, though, where genetic information is fully predictive of the disease. For
example, Huntington’s disease is a prime example of a one hundred percent predictive value, since if you have
the Huntington’s gene, it is only a matter of time before you develop the disease. See What Is Huntington’s
Disease (HD)?, HUNTINGTON’S DISEASE SOC’Y OF AM., http://hdsa.org/what-is-hd/ (last visited Apr. 27,
2015).
174 U.S. Nat’l Library of Med., What Does It Mean to Have a Genetic Predisposition to a Disease?,
GENETICS HOME REFERENCE, http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/predisposition (last
updated Apr. 20, 2015).
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complex. First, having the gene puts an individual at higher risk for the
relevant disease, much like having a particular biomarker puts him or her at
higher risk.175 But merely having the gene is, in most cases, not sufficient to
manifest the disease.176 The gene almost always needs to interact with the
environment and be switched on or off, so to speak, for disease manifestation
to occur.177 In most cases, genetic testing can only determine whether a
particular gene or genes are present, which in turn signals a predisposition for a
certain disease or condition associated with that gene or genes.178 Whether that
predisposition results in the disease or condition in the long run ultimately
depends on myriad factors that cannot be predicted.179
For example, the apoE4 gene implicated in Alzheimer’s disease increases
an individual’s risk for developing the disease.180 A carrier with one copy of
the apoE4 gene is three times more likely than someone who doesn’t have any
copies of apoE4 to develop Alzheimer’s disease.181 And a carrier with two
copies of the apoE4 gene is roughly twelve times more likely than someone
who doesn’t have any copies of the gene to develop Alzheimer’s disease.182
But even with the increased risk that accompanies being a carrier of the apoE4
gene, it is impossible to know how that gene will interact with that individual’s
environment and whether that gene–environment interaction will switch on the
gene in such a way that results in Alzheimer’s disease, as is evident in the fact
that the apoE4 gene is far from determinative when it comes to developing
Alzheimer’s disease.183 One-third of Alzheimer’s disease patients do not carry
any copies of the apoE4 gene, and some people who carry two copies of the
apoE4 gene never develop the disease.184
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See infra notes 180–84 and accompanying text.
For a more in-depth discussion of gene–environment interaction, see Ruth Ottman, Gene–Environment
Interaction: Definitions and Study Designs, 25 PREVENTATIVE MED. 764 (1996).
177 See id.
178 See Walter C. Willett, Balancing Life-Style and Genomics Research for Disease Prevention,
296 SCIENCE 695 (2002), available at http://www.sciencemag.org/content/296/5568/695.full.pdf.
179 See id. There are certain genetic conditions that do not need to interact with the environment to be
“switched on.” See supra note 173.
180 See Jim Schnabel, Why Does apoE4 Make Alzheimer’s More Likely?, DANA FOUND. (July 7, 2011),
http://www.dana.org/News/Details.aspx?id=43163.
181 Id.
182 Id.
183 See NAT’L INST. ON AGING, ALZHEIMER’S DISEASE GENETICS FACT SHEET 5 (2011),
http://www.nia.nih.gov/sites/default/files/alzheimers_disease_genetics_fact_sheet_0.pdf.
184 See id. at 4.
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If neuroimaging information shows identifiable structural and functional
changes that differ from a healthy person’s scans,185 then as long as that
information is strongly and fairly reliably correlated with disease manifestation
and onset, neuroscience information may be even more useful than genetic
information is in a predictive sense. Genes need to be switched on and off by
the environment, which is very unpredictable.186 Brain scans, however, show
actual changes in the brain that may be indicative of a cause or effect of some
disease that will develop or manifest down the road.187
A recent study in the journal Neurology found that a PET scan showing
high levels of beta-amyloid was a better predictor of future Alzheimer’s
disease onset than a genetic test for the apoE4 gene.188 If neuroscience
information is more useful than genetic information in predicting disease onset,
there is a strong argument that it is more deserving of discrimination protection
because it is even more likely to be abused than predictive genetic information.
C. Closing the Gap
Closing the gap in protection could be achieved fairly easily. There are a
number of acceptable solutions. This section will briefly suggest a few of the
simplest ways that this could be achieved.
The easiest way to close the gap would be to include predictive
neuroscience information under health-status-related factors in the same way
that genetic information is already listed in ACA.189 This would quickly and
effectively close the gap by covering all predictive information, preventing
health insurers from discriminating on the basis of any predictive information
instead of just genetic information, as ACA currently reads.190 There are two
ways
to
include
predictive
neuroscience
information
under
health-status-related factors in ACA. First, ACA could be amended to add
another health-status-related factor. The alternative, and far more likely
solution, would be for the Secretary of Health and Human Services to act
under the final open health-status-related factor in ACA by determining that
predictive neuroscience information should appropriately be included as a

185
186
187
188
189
190

See Illes & Kirschen, supra note 172.
See Ottman, supra note 176.
See Honey et al., supra note 167.
Brain Plaque vs. Alzheimer’s Gene, supra note 102.
See 42 U.S.C. § 300gg-4(a)(6) (2012).
See id.
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factor.191 This solution would be the quickest and most practical option since
the Secretary could act in her agency capacity without congressional action.192
Other more complex methods would include extending Title I of GINA to
apply not only to genetic information but also to predictive neuroscience
information, or drafting a new GINA-like bill specifically for predictive
neuroscience information.193 Though more extensive effort would be necessary
to pursue either of these two options, there could be some merit in considering
them. However, given the relative ease and practicality of the
health-status-related factor option, implementation of these alternative options
seems unlikely.
CONCLUSION
The lack of protection for predictive neuroscience information represents a
gap in the existing health insurance discrimination protections found in
HIPAA, GINA, and ACA. This gap allows health insurers to use predictive
neuroscience information to discriminate when determining premium rates and
coverage in the large-group and self-insured markets. Despite the expansive
protections afforded by ACA and GINA for predictive genetic information, the
failure to extend the full measure of this protection to predictive neuroscience
information is highly problematic.
Health insurance discrimination has received significant attention in recent
years with the passage of GINA and ACA in 2008 and 2010, respectively.
While their provisions have expanded protections against unfair health
insurance discrimination markedly, there remains a gap in protection for
predictive neuroscience information in the large-group and self-insured
markets. The reason this gap is significant is because it allows health insurers
to undercut existing provisions protecting predictive genetic information by
turning to unprotected predictive neuroscience information, which can
effectively tell them the same thing, and in some cases is even more reliable
from a predictive standpoint than genetic information. It is important that the
gap in protection be addressed as soon as possible to prevent this type of unfair
discrimination from taking root.
191 See id. § 300gg-4(a)(9) (“Any other health status-related factor determined appropriate by the
Secretary.”).
192 See id.
193 For more on this idea as applied to the employment context, see Stephanie A. Kostiuk, Note, After
GINA, NINA? Neuroscience-Based Discrimination in the Workplace, 65 VAND. L. REV. 933 (2012).
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Closing the gap would likely be a fairly simple and straightforward matter,
requiring only the addition of a health-status-related factor in ACA for
predictive neuroscience information. This would explicitly close the existing
gap in protection and ensure that the millions of people who make up the
large-group and self-insured health insurance markets are afforded the same
protection as their counterparts in the small-group and individual markets. This
simple fix would bring protection for predictive neuroscience information in
line with existing health insurance protections for predictive genetic
information and foreclose discrimination on the basis of all predictive
information. Closing this gap could easily be achieved with minimal effort and
would have maximal impact on those who are outside the scope of current
protections.
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